Radioligand Therapy (RLT) Market 2025 – Market Size & Segments Analysis, Industry Trends, Manufacturers Analysis, Opportunities and Forecast 2034
Page: 215 | Report Code: LS250310 | Research Suite: Report (PDF) & Market Data (Excel)
NOTE: Due to exhaustive nature of content, full ToC can't be uploaded. Please request Sample Pages to receive full table of content.
Radioligand therapy (RLT) is a novel and targeted way to
treat cancer that utilizes a mixture of a ligand that specifically targets
cancer cells expressing certain biomarkers, and a therapeutic radionuclide that
delivers cytotoxic radiation directly to these cells. This approach is
particularly effective in treating various types of cancer, such as advanced
prostate cancer, lymphoma, and neuroendocrine tumors.
MARKET
OVERVIEW
The radioligand therapy market is valued at approximately USD 7.44 billion in 2023 and is projected to reach USD 20.01 million by 2034 exhibiting a compound annual growth rate (CAGR) of 9.41% during the forecast period of 2024-2034. Radioligand therapy is significant because of its targeted strategy, which maximizes therapeutic efficacy while minimizing side effects; its applicability across various cancers; its potential for personalized medicine; and its growing acceptance backed by clinical evidence.
GROWTH
DRIVERS
The increasing prevalence of hard-to-treat cancers, like
neuroendocrine tumors and metastatic prostate cancer, is one of the main
factors propelling the market for radioligand therapy. Conventional therapies
such as chemotherapy or surgery often fail to treat these cancers effectively,
creating a significant demand for innovative treatment options. For instance,
according to the World Health Organization, there were 1,467,854 new cases of
prostate cancer in 2022. Additionally, it is the 4th most common cancer
worldwide and the 2nd most common cancer in men. The increasing patient
population is leading to an interest in targeted therapies such as RLT.
The precision and effectiveness of cancer treatments are
significantly enhanced by the development of advanced radiopharmaceuticals. The
development of Isotopes such as Lutetium-177 (Lu-177) and Actinium-225 (Ac-225)
is leading to more targeted delivery of radiation delivery to cancer cells
while preserving healthy tissues. The FDA has also authorized Lutathera
(Lu-177-DOTATATE) for the treatment of neuroendocrine tumors. These
advancements not only enhance the outcome of treatment but also broaden the
range of cancers that can be treated with RLT.
MARKET
SEGMENTATION:
By Isotope
-
·
Lutetium-177 (Lu-177)
·
Radium Ra 223 Dichloride
·
Fluorine-18
·
Gallium-68
·
Other Isotopes
By Targeted
Receptor -
·
Prostate-Specific Membrane Antigen
(PSMA)
·
Somatostatin Receptor (SSTR)
·
Epidermal Growth Factor Receptor (EGFR)
·
Other Targeted Receptors
(Gastrin-Releasing Peptide Receptor (GRPR), etc.)
By Indication
-
·
Prostate Cancer
·
Neuroendocrine Tumors (NETS)
·
Breast Cancer
·
Other Indications
By End
User -
·
Hospitals
·
Surgical Care Centers
·
Other End Users
By
Region -
·
North America
·
Europe
·
Asia Pacific
·
Latin America
·
Middle East & Africa
Radioligand
Therapy Market By Isotope Segment Review:
Lutetium-177 (Lu-177) is a beta-emitting radionuclide with favorable physical and chemical properties that make it highly effective for treating various cancers. The adoption of Lu-177-based therapeutics is primarily driven by the increasing incidence of cancers worldwide, including prostate cancer and neuroendocrine tumors. This growing patient population, requiring effective and targeted treatments, is significantly boosting demand for Lu-177-based RLT.
Radioligand
Therapy Market By Targeted Receptor Segment Review:
In 2024, PSMA segment is anticipated to hold the largest
share of the market due to their effectiveness in treating prostate cancer. The
growing prevalence of prostate cancer and advancements in imaging techniques is
expected to increase the adoption of PSMA-targeted therapies.
Radioligand
Therapy Market By Indication Segment Review:
The rising prevalence of prostate cancer worldwide is the
main factor propelling the market for radioligand therapy for this form of
cancer. Additionally, the awareness about the benefits of radioligand therapy
for prostate cancer is increasing among healthcare professionals and patients,
which is consequently fueling market growth.
Radioligand
Therapy Market By End User Segment Review:
In 2024, hospitals segment is anticipated to hold the
largest share of the market due to their capacity to provide comprehensive care
and advanced treatment options. They are equipped with the necessary
infrastructure, such as nuclear medicine departments, radio-pharmacy services,
and qualified personnel like medical physicists and oncologists.
Radioligand
Therapy Market By Region Segment Review:
The market exhibits significant regional variations, with
North America leading the market in 2024 due to its advanced healthcare
systems, high levels of investment in cancer research, and the presence of key
players in the pharmaceutical industry.
Radioligand
Therapy Market Regional Synopsis:
The North America is anticipated to dominate the global
market for radioligand therapy due to the increasing prevalence of cancer,
region’s robust clinical trial infrastructure and ongoing research initiatives,
favorable government investments in cancer research, and supportive regulatory
environments.
The Europe is another crucial market, expanding primarily
due to its robust healthcare systems and ongoing clinical trials focused on radiopharmaceuticals.
The market is expanding further due to the European Union's emphasis on
expanding cancer treatment alternatives through funding and research projects.
The market in Asia Pacific is growing rapidly due to the
rising cancer incidences in the region and increasing investments in healthcare
infrastructure.
In Latin America, the market is poised for steady growth due
to the rising cancer rates and improvements in healthcare access.
The market in the Middle East and Africa region is growing due to the increasing cancer incidence rates, supportive government initiatives, and heightened awareness among healthcare professionals.
Radioligand
Therapy Market Key Challenges:
The high cost of treatment is one of the most significant
obstacles to the widespread adoption of radioligand therapy. These treatments
are often associated with high development, manufacturing, and administration
costs. This financial burden is expected to limit its access for patients,
particularly in healthcare systems where budget constraints are prevalent.
The reimbursement landscape for radioligand treatments is
often complex and differs significantly between different geographical regions
and healthcare providers. The process of navigating these processes often becomes
challenging for both patients and healthcare providers, leading to delays in
treatment access or even denial of coverage for certain therapies.
Radioligand
Therapy Market Competitive Landscape:
The global market for radioligand therapy is characterized
by a diverse range of established pharmaceutical companies, emerging biotech
firms, and contract research organizations (CROs), each striving to enhance
their market presence through various strategies such as robust R&D
investments, strategic partnerships, expanding therapeutic indications,
effective navigation of regulatory processes, marketing efforts aimed at
raising awareness, demonstrating cost-effectiveness, and geographic expansion
into emerging markets.
Companies are investing significantly in research and
development (R&D) to evaluate the efficacy and safety of new radioligand
therapies. This involves exploring new radiopharmaceuticals while improving
existing therapies. Through thorough clinical testing, companies aim to advance
their product pipelines, gain regulatory approval, and provide novel treatments
that address unmet medical needs.
Radioligand
Therapy Market Key Players:
·
Bayer AG
·
Novartis
·
Debiopharm
·
ITM Isotope Technologies Munich SE
·
Precirix
·
IQVIA
·
AstraZeneca
·
AdvanCell
· Other Key & Niche Players